Milestone Pharmaceuticals Inc.
MIST•NASDAQ•Healthcare•Biotechnology

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company’s lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOJoseph Oliveto
Founded2003
Employees33
CountryCanada
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websitewww.milestonepharma.com
Phone514 336 0444
Address
1111 Dr. Frederik-Philips Boulevard, Suite 420 Montreal, QC H4M 2X6 Canada

Corporate Identifiers

CIK0001408443
CUSIP59935V107
ISINCA59935V1076
SIC2834

Leadership Team & Key Executives

Joseph G. Oliveto M.B.A.
Chief Executive Officer, President and Director
Amit Hasija
Chief Financial Officer and Executive Vice President of Corporate Development
Dr. David B. Bharucha FACC, M.D., Ph.D.
Chief Medical Officer
Dr. Philippe Douville M.B.A., Ph.D.
Founder, Strategic Advisor and Member of Scientific Advisory Board
Jeffrey Nelson
Chief Operating Officer
Roshan Girglani
Vice President of Marketing
Jeff Moore
Vice President of Sales
Dr. Philip T. Sager FACC, FAHA, FHRS, M.D.
Chief Medical Advisor and Member of the Scientific Advisory Board
Dr. Guy Rousseau
SVice President of Regulatory Affairs and Quality Management
Lorenz Muller
Chief Commercial Officer